When we break a bone, the damage is obvious. But not every health condition in life is so clear-cut. Many ailments are considered a "silent disease" because they don't have obvious symptoms. Instead, ...

Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...

In the inaugural episode of "Unlocking the Fatty Liver Mistry," Dr. Neeraj Mistry, Chief Medical Officer of the Fatty Liver Foundation, shares crucial insights on the often-overlooked health ...

Non-alcoholic fatty liver disease (NAFLD) is the physiological manifestation of obesity in the liver. The prevalence of NAFLD has increased from 25.24% in 2015 to 29.38% in 2021, and this condition ...

This discovery highlights how studying energy production at the cellular level could lead to effective treatments for obesity ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

The global fatty liver treatment market, valued at approximately USD 20 Billion in 2022, is anticipated to witness ...

Obesity is a chronic disease with many contributing factors ... seek out guidance from pediatric obesity specialists and ...

Results from Phase 2b FASCINATE-2 study of denifanstat published in The Lancet Gastroenterology & Hepatology Successful completion of end-of-Phase 2 interactions with FDA on the development of ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than ...

More than a third (38%) of adults globally have MASLD, which is expected to increase to more than 55% by 2040. 2 There are ...

Obesity is a chronic disease with many contributing factors; family history, access to healthy foods, hormonal and metabolic ...